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Abstract
Background: Currently, only few techniques are available for quantifying systemic metastases in preclinical model. Thus
techniques that can sensitively detect metastatic colonization and assess treatment response in real-time are urgently
needed. To this end, we engineered tumor cells to express a naturally secreted Gaussia luciferase (Gluc), and investigated its
use as a circulating biomarker for monitoring viable metastatic or primary tumor growth and their treatment responses.
Methodology/Principal Findings: We first developed orthotopic primary and metastatic breast tumors with derivative of
MDA-MB-231 cells expressing Gluc. We then correlated tumor burden with Gluc activity in the blood and urine along with
bioluminescent imaging (BLI). Second, we utilized blood Gluc assay to monitor treatment response to lapatinib in an
experimental model of systemic metastasis. We observed good correlation between the primary tumor volume and Gluc
concentration in blood (R
2=0.84) and urine (R
2=0.55) in the breast tumor model. The correlation deviated as a primary
tumor grew due to a reduction in viable tumor fraction. This was also supported by our mathematical models for tumor
growth to compare the total and viable tumor burden in our model. In the experimental metastasis model, we found
numerous brain metastases as well as systemic metastases including bone and lungs. Importantly, blood Gluc assay
revealed early growth of metastatic tumors before BLI could visualize their presence. Using secreted Gluc, we localized
systemic metastases by BLI and quantitatively monitored the total viable metastatic tumor burden by blood Gluc assay
during the course of treatment with lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2.
Conclusion/Significance: We demonstrated secreted Gluc assay accurately reflects the amount of viable cancer cells in
primary and metastatic tumors. Blood Gluc activity not only tracks metastatic tumor progression but also serves as a
longitudinal biomarker for tumor response to treatments.
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Introduction
The evaluation of the metastatic tumor burden is complicated.
Oftentimes, it can only be assessed at the sacrificial end point and
longitudinal information on the progression remains unknown. This
is especially problematic for evaluating treatments since tumor size
at the start of treatment can vary considerably. Bioluminescence
imaging (BLI) is a powerful tool for localizing and quantifying
metastatic tumor growth. However, the spatial resolution of BLI is
relatively poor and the optical signal propagation through living
tissue compromises sensitivity and complicates accurate measure-
ments, thus rendering the evaluation of small metastatic cell clusters
rather difficult, if not impossible [1]. Secreted reporters in the blood
have emerged as promising tools for the detection, quantification
and noninvasive monitoring of biological processes in experimental
models [2,3,4,5,6,7,8,9]. Recently, naturally secreted Gaussia
luciferase (Gluc) from the marine copepod Gaussia princeps has been
demonstrated to be a sensitive and quantitative method for
evaluating cancer cells in vivo [2]. Gluc has several advantages over
other commonly used reporters for in vivo imaging. Gluc is 2000-fold
more sensitive than firefly or Renilla luciferases and 20,000-fold
more sensitive than the secreted alkaline phosphatase [4,10].
Further, since Gluc is secreted, its concentration in the blood
correlates with expression level in a given biological system [2,11].
Here, we seek to evaluate secreted Gaussia luciferase as a novel
biomarker for longitudinal monitoring of systemic metastasis.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8316We engineered MDA-MB-231BR (231BR) cells, a subline of
human breast adenocarcinoma cell line (MDA-MB-231) selected
from brain metastasis, to express Gluc in an experimental
metastasis model [12]. In this model numerous brain metastases
as well as systemic metastases including bone or lungs are
observed. We utilized secreted Gluc to track the progression of
231BR cells that metastasized to various organs. To monitor
treatment response by secreted Gluc assay, we treated mice with
lapatinib, a dual kinase inhibitor that targets EGFR and Her2
[13]. Lapatinib was shown previously to reduce the outgrowth of
brain tumors of MDA-MB-231BR-Her2 (231BR-Her2) [14]. Here
we successfully demonstrate secreted Gluc as a new measure of
viable tumor burden in primary and metastatic tumor models. We
also show for the first time that blood Gluc assay allows the
monitoring of treatment response in a metastasis model by
synchronizing the treatment initiation with Gluc-matched tumor
burden, a parameter typically difficult to determine. Our reported
method will facilitate the study of the biology and treatment of
metastatic disease using animal models.
Results and Discussion
Monitoring Orthotopic Primary Tumor Progression by
Gluc Activity in Blood and Urine
To correlate total primary tumor burden with Gluc activity, we
first implanted 231BR-G cells orthotopically in the mammary fat
pad to grow as a primary tumor. We compared the Gluc assay
signals in the plasma, whole blood, and urine. Gluc signals were
highest in plasma, followed by blood, and urine that exhibited the
lowest signal (Fig. 1A, B). Even though Gluc in plasma gave a
higher signal, the signal-to-background ratio (SG/BG ratio) of
Gluc in blood was comparable to that of Gluc in plasma, and both
were higher than that of the urine by two orders of magnitude
(Fig. 1C, D). Since additional centrifugation step and twice more
volume of blood are required for plasma collection, we used blood
Gluc for our subsequent study.
Primary tumor growth was assessed with three different
modalities - Gluc activity, tumor volume estimation, and BLI
signal. The blood Gluc value correlated well (R
2=0.84) with
tumor volume. Urine Gluc value also correlated with the tumor
volume but to a lesser extent (R
2=0.55) (Fig. 2A, B). We also
confirmed that primary tumors detected with blood Gluc assay
could also be detected with whole body BLI (Fig. 2C).
Whole Blood Gluc Activity Reflects Viable Tumor Volume
It is not clear whether blood Gluc value accurately represents
tumor volume. To investigate their relationship closely, we
analyzed blood Gluc value and primary tumor volume over 9
weeks. Overall, blood Gluc activity correlates with tumor volume
well (Fig. 3A). Interestingly, we observed that the slope of the line
of linear regression decreases as the range of cumulative tumor
volume increased (Fig. 3B). After grouping the tumors in three
Figure 1. Comparison of Gluc activity in whole blood, plasma, and urine. 231BR-G tumor fragments were implanted in mammary fat pad.
Blood and urine samples were collected from tumor-bearing animals and Gluc activity was evaluated in different sample volumes. A, The relative
Gluc signal is plotted against different volume of each sample. Results shown are from three different tumor-bearing animals. Relative Gluc signal is
obtained based on the corresponding 2 ml urine Gluc signal. B, The Gluc values from 10 mL samples normalized to urine Gluc values are plotted. C,
The Signal-to-background ratio (SG/BG) was plotted against sample volume. The background is defined as the signal obtained from samples
collected from control mice without tumors. Results are normalized by the corresponding 2 ml urine SG/BG. D, SG/BG ratio of the 10 mL volume of
samples normalized to urine Gluc signals are plotted. All results were presented as mean 6 SE (n=3).
doi:10.1371/journal.pone.0008316.g001
Secreted Gluc as a Biomarker
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8316different volume ranges (0–100, 0–300, 0–800 mm
3), the respec-
tive linear regression line shows a consistent decrease in the slope
as the group includes bigger tumors (Fig. 3A and inset table, and
Fig. 3B). We hypothesized that this phenomenon may be in part
due to an increasing fraction of necrotic tissue in the bigger tumor
(Fig. 3C and Methods). Since Gluc is secreted by viable tumor
cells, the blood Gluc signal would reflect total viable tumor volume
while size-measurement represents total tumor volume including
necrotic tissue. To understand this mechanistically, we developed
a simple mathematical model to explain the observed tumor
growth data of total tumor volume and viable tumor volume with
blood Gluc value (Fig. 3D, Table S2). We assumed i) blood Gluc
signal is proportional to the volume of viable tumor cells, ii) tumor
volume is proportional to the number of total tumor cells, and iii)
the viable tumor rim thickness is constant with central tumor
necrosis. To convert the blood Gluc activity into the correspond-
ing tumor volume, we normalized each blood Gluc value - by
dividing Gluc value at day 0 and by multiplying the corresponding
tumor volume at day 0 (defined by tumor volume of ,10 mm
3).
The curve fittings were made by two spherical tumor growth
models: Model 1 is based on exponential tumor growth curve for
tumor volume measurement, and Model 2 is based on central
necrosis and a viable tumor rim. The fitting of Model 2 with
corresponding tumor volume from Gluc measurements provides
the viable tumor rim of 0.6 mm that agrees with the viable tumor
rim observed in the hematoxylin & eosin (H&E) analyses in Fig. 3C
(Details in Supporting Information S1). These data support that
blood Gluc activity reflects viable tumor burden. In addition,
blood Gluc assay potentially provides more precise measurement
since manual tumor volume measurement is inherently operator
dependent.
Real-Time Monitoring of Metastatic Tumor Progression
with Blood Gluc and Localization of Metastases with Gluc
Bioluminescence Imaging
We hypothesized that blood Gluc assay provides a sensitive
measurement for monitoring of systemic metastasis and BLI with
Gluc shows localization of metastasis. To test this hypothesis, we
utilized an experimental metastasis model by injecting 231BR-
Her2-G cells into the arterial circulation. We observed that blood
Gluc signal sharply increased one day after cell injection and then,
the signal dropped precipitously to the basal level three days after
indicating massive loss of injected cells after initial short time
survival (Fig. 4A). Blood Gluc value in 8 out of 10 mice reached 1
Relative Light Unit (RLU)/s at 14–21 days after inoculation.
Interestingly, all animals with blood Gluc value above 1 RLU/s
eventually developed systemic metastasis including bone and brain
(Fig. 4C, D). We confirmed these data with 4 separate experiments.
All 46 out of 77 mice with blood Gluc values greater than 1 RLU/
s at 14–35 days after intra-cardiac injection, developed systemic
metastasis (Table S1). In contrast, the 31 mice that did not have
blood Gluc values above 1 failed to develop metastasis. Thus,
Figure 2. Monitoring of Gluc activity in blood, urine, and bioluminescence imaging (BLI) of orthotopic breast cancer model. 231BR-G
tumor fragments were implanted in the mammary fat pad. A–C, Blood and urine were collected twice a week from 4 to 63 days after implantation
and Gluc activity was acquired using a luminometer (n=3; 10 ml of blood and 5 ml of urine). At the same time, tumor volume was quantified by
caliper measurements. A, Representative time-course data of tumor volume, blood and urine Gluc activity in one representative animal, B,
Correlation of the blood or urine Gluc value to the tumor volume, C, Representative bioluminescent images with concurrent measurement values of
blood Gluc value, tumor volume, and BLI signal at days 23, 30, and 59 after tumor implantation.
doi:10.1371/journal.pone.0008316.g002
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colonization and provides a means for quantitative evaluation of
metastatic tumor burden in real-time. In most cases, we could not
localize the metastatic sites with BLI when blood Gluc value was
below 10 RLU/s (Fig. 4B). Big or superficial tumors were
detectable with BLI (Fig. 4B, C) while small or deeply located
tumors were not always recognizable (Fig. 4B, D). Even though
BLI provides a powerful tool for longitudinal observations, the
quantification of bioluminescent signal is limited due to the light
scattering and absorption through the tissue [15,16]. We next
compared the BLI signal of Gluc with conventional Firefly
luciferase (Fluc). We performed a control experiment using by Fluc
and Gluc double-transfected cell line in the experimental
metastasis model. Both showed comparable signal level and
similar localization of metastasis (Fig. S1B,S 1 C). The peak
emission wavelength of Gaussia luciferase is 480 nm [10], and
therefore it has higher tissue absorption as compared to that of
firefly luciferase with 612 nm at 35uC [17]. Despite this limitation,
Gluc BLI is shown to be comparable to Fluc for imaging
metastatic tumors due to its high photon flux. These results suggest
that by engineering a non-secreted version of Gluc, this luciferase
can potentially be more sensitive than Fluc in localizing metastasis
in vivo. In fact, it has been shown recently that by either cloning an
ER-retention signal or a transmembrane domain at the C-
terminus of Gluc, that over 10-fold of this protein is retained in/on
the cell leading to nearly one order of magnitude higher sensitivity
in localizing cells in vivo as compared to the wild-type secreted Gluc
[10,18]. It should be noted that the 1RLU/s threshold value for
detecting and initiating the treatment of metastasis was specific to
the particular model system and luminometer setting used in this
study. The threshold value is dependent on multiple variables
including the sensitivity of a luminometer and levels of expression
of Gaussia luciferase in a given cell line. In addition, the entry of
Gluc into the circulation could be affected by the microenviron-
ment and interaction between tumor and host cells.
Blood Gluc Assay Provides Real-Time Monitoring of
Treatment Response for Systemic Metastasis Progression
Next we tested whether blood Gluc assay can be used to
monitor treatment response in real-time with our metastasis
model. We used the 231BR-Her2-G cells in the experimental
metastasis model to examine whether lapatinib could inhibit
systemic metastatic progression. When blood Gluc value reached
at 1 RLU/s, mice were treated with lapatinib (100 mg/kg bid) or
vehicle. Gluc value-matched starting points would minimize
variations in initial metastatic tumor burden among treated
Figure 3. Blood Gluc assay reflects viable tumor burden. 231BR-G tumor fragments were implanted in the mammary fat pad. Blood Gluc and
tumor volume were assessed twice a week (n=24). A, Scatter plot of blood Gluc values and tumor volumes up to 9 weeks after the implantation.
Linear regression was analyzed for three tumor volume ranges and specified with slopes and R
2 values. B, Slope of the line of linear regression line
with respect to the cumulative tumor volume range. C, Viable tumor fraction analyzed using H&E stains of central tumor sections. Final tumor sizes
are segregated into three groups and viable fraction is shown as mean 6 SE (n=3–5 tumors per group, small: 0–100, intermediate: 100–300, large:
300–800 mm
3). *, P , 0.05 by Mann-Whitney U-test when small and intermediate tumors are compared to large tumors. Two illustrative figures with
viable tumor segregation are shown (red: viable tumor, green: necrotic area). Scale bar is 1 mm. D, Mathematical modeling to fit the measured total
tumor volume and viable tumor volume estimated from blood Gluc activity. Model 1 fits total tumor growth and Model 2 fits viable tumor growth.
doi:10.1371/journal.pone.0008316.g003
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With blood Gluc value, we showed that lapatinib suppressed the
progression of systemic metastasis (Fig. 5A). Metastatic tumor
progression was concurrently monitored by BLI imaging (repre-
sentative BLI images in Fig. 5B). In control mice, we observed
more extensive metastases compared to treated mice. We then
investigated the effects of lapatinib treatment on mice survival by
using Gluc-matched treatment initiation in Fig. 5C. All three mice
in the control group did not survive beyond 42 days while two out
of four treated mice survived much longer up to day 61 and 99,
respectively. With the use of blood Gluc level, we showed that
lapatinib significantly delayed the systemic tumor progression and
prolonged survival in this model. Thus, blood Gluc activity can be
used as a quantitative biomarker for longitudinal monitoring of
tumor progression and treatment response in metastatic disease.
The field of metastasis research traditionally used Fluc as the
reporter for bioluminescence imaging of tumor burden in vivo.
The application of the Gluc reporter for blood assay will facilitate
the detection of early systemic metastasis, particularly at a stage
that is still not detectable by Fluc or Gluc-based bioluminescence
imaging. Furthermore, the Gluc utilizes a different substrate (i.e.
coelenterazine) than Fluc (i.e. luciferin) and this allows simulta-
neous monitoring of tumor burden and signaling pathway activity
[19,20]. In summary, we demonstrated that blood Gluc assay
accurately measures the amount of viable cancer cells in primary
and metastatic tumors. Blood Gluc assay is highly sensitive and it
provides a novel way to longitudinally monitor metastatic
progression and response to treatment. This technology will aid
in the study of tumor metastasis and the development of strategies
in treating this devastating disease.
Materials and Methods
Ethics Statement
All animal procedures were performed following the guidelines
of Public Health Service Policy on Humane Care of Laboratory
Animals and approved by the Institutional Animal Care and Use
Committee of the Massachusetts General Hospital. Animals were
anesthetized with ketamine/xylazine (100/10 mg/kg, intraperito-
neal injection) for all experimental procedures.
Cell Lines and Cell Culture
The 231BR cell line and its human epidermal growth factor
receptor 2 (Her2)-overexpressing counterpart (231BR-Her2) both
expressing green fluorescent protein (GFP) were kindly provided
by Dr. Patricia S. Steeg (National Cancer Institute, Bethesda, MD)
[21]. The 231BR and 231BR-Her2 cells were maintained in
Dulbecco’s modified Eagle Medium (DMEM, Mediatech, Man-
assas, VA) supplemented with 10% fetal bovine serum (FBS,
Atlanta biologicals, Lawrenceville, GA) and 1% penicillin-
streptomycin solution (SIGMA, St. Louise, MO).
Gluc Transfection
The lentiviral vector carrying an expression cassette encoding
Gluc and cerulean fluorescent protein (CFP, LV-Gluc-CFP)
separated by an internal ribosomal entry site has been generated
Figure 4. Real-time monitoring of metastatic tumor progression with blood Gluc assay and localization of metastases with
bioluminescence imaging. A, 231BR-Her2-G cells were injected in the heart (n=10). Blood Gluc was measured at day 0 (before injection), 1, 3
days, and weekly. B, Longitudinal BLI with concurrent blood Gluc values (four representative animals are shown). Each Gluc value is shown in the
right lower inset. Bold red values are the animals whose metastases are detectable in the BLI. C–D, Ex vivo images of spine (C) and brain (D)
metastatic tumors overlayed with GFP signals taken with the same IVIS system. Scale bar is 5 mm.
doi:10.1371/journal.pone.0008316.g004
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with LV-Gluc-CFP – 231BR-G and 231BR-Her2-G - at a
multiplicity of infection of 50 as previously described [2]. CFP
positive cells were sorted with a FACSAria cell sorter (BD
Biosciences, San Jose, CA), at the Flow Cytometry Facility at the
Ragon Insitute (Massachusetts General Hospital, Boston, MA).
Orthotopic Breast Cancer Model (Mammary Fat Pad
Model)
Tumor fragments from established 231BR-G tumors (volume of
200–300 mm
3) were implanted in the mammary fat pad (MFP) of
5–7 weeks-old female nude mice. Tumor size was measured by a
caliper. The following formula was used to calculate tumor
volumes = (shorter diameter)
26(longer diameter)/2. Tumors
were resected and used for H&E staining.
Experimental Metastasis Model (Intracardiac Injection
Model)
6–7 weeks old female nude mice were injected with 0.25610
6
231BR-Her2-G cells in 0.1 ml PBS via the left ventricle [21]. Mice
were euthanized when animals showing clinical symptom of
prolonged distress or when they showed signs of neurological
impairment or lost more than 20% of body weight defined as a
survival end point. The brain, bone, and the other organs were
harvested and immediately evaluated for GFP using fluorescent
microscopy.
Blood/Urine Gluc Assay
Measurement of secreted Gluc was performed as previously
described [11]. Briefly, blood was drawn from making a slight
nick in the tail-vein. Urine was collected directly from urethral
openings. 10 ml of blood was collected and mixed with 2 mlo f
50 mM EDTA. All the samples used for Gluc assay contain
20% (vol/vol) EDTA solution. Blood or urine sample was then
transferred to a 96-well plate. Gluc activity was measured using
a plate luminometer (MLX luminometer, Dynex technologies,
Chantilly, VA). The luminometer was set to automatically
inject 100 ml of 100 mM coelenterazine (CTZ, Nanolight,
Pinetop, AZ) in PBS and photon counts were acquired for
10 sec.
Viable Tumor Quantification
H&E stained section of the MFP tumors (one central cross
section per tumor) were examined. Based on H&E staining, the
region of viable tumor area in each tumor section was determined
by a pathologist, blinded to the study. Most tumors had a
predominantly necrotic core with a viable rim. The area of the
viable tumor was quantified with respect to the full cross-sectional
tumor area by a custom-written Matlab program. It is noteworthy
that some breast tumors (e.g. MCaIV tumors) do not have clear
viable tumor rim (unpublished observation). Since the mathemat-
ical model has not been tested in other tumor models, it warrants
further examinations in the future.
Figure 5. Blood Gluc assay provides real-time monitoring of treatment response for systemic metastasis progression. 231BR-Her2-G
cells were injected into the heart. When blood Gluc value reached at 1 RLU/s, mice were treated with lapatinib. A–B, blood Gluc and BLI were
assessed weekly (n=16 per group). Mice were sacrificed 28 days after treatment for sample collection. *, P , 0.05 by Mann-Whitney U-test. Data
shown as mean 6 SE. B, BLI images of representative animals in each group (dorsal and ventral view) of at day 28 are shown. Imaging was done
individually, C, Kaplan-Meier survival curve in lapatinib treated mice vs control animals (treatment =4, control =3).
doi:10.1371/journal.pone.0008316.g005
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Lapatinib was purchased from GlaxoSmithKline (Philadelphia,
PA). Each lapatinib tablet was grounded and was dissolved in
sterile water of 0.5% Tween80 (Sigma). Lapatinib treatment
started when the whole blood Gluc value reached at 1 RLU/s.
Lapatinib (100 mg/kg bodyweight) was administered twice a day
by oral gavage.
Bioluminescence Imaging
Individual animal was anesthetized and BLI was performed
immediately after retro-orbital injection of CTZ (4 mg/kg body
weight unless otherwise specified). IVIS Imaging System (Lumina
II, Caliper Life Sciences, Hopkinton, MA) was used for BLI
recording. The image acquisition time was in the range of 15 sec
to 1 min. Post-processing and quantification was performed using
Living Image software 3.0 coupled to the IVIS system. For BLI
analysis of primary mammary tumors, photon flux was calculated
for each mouse by using a circular region of interest encompassing
the primary tumor in supine position.
Statistical Analysis
Data were expressed as the mean 6 SE. Statistical analysis was
performed using two-sided Mann-Whitney U-test. Statistical
significance was defined as P , 0.05. The survival curves were
estimated by the Kaplan-Meier method.
Supporting Information
Figure S1 Comparison of Fluc and Gluc for bioluminescence
imaging of metastasis. MDA231BR cells were co-infected with 2
lentivirus vectors encoding Gluc-CFP and Fluc-mCherry. (A)
Fluorescent microscopy images showing that these cells are equally
expressing these reporters. Scale bar 50 mm. (B) MDA231BR cells
expressing both Gluc and Fluc were inoculated via intracardiac
injection into 7 weeks old female nude mice. Five weeks after
inoculation, mice were imaged with either Gluc BLI after i.v.
injection of coelenterazine (8 mg/kg body weight), or Fluc BLI
after i.p. injection of D-luciferin (150 mg/kg body weight). Fluc
BLI imaging was done at least 3 hrs after Gluc BLI imaging. (C)
Quantification of Fluc and Gluc bioluminescent signals (photon
flux) from 9 different metastatic regions in three animals.
Found at: doi:10.1371/journal.pone.0008316.s001 (2.14 MB TIF)
Table S1 The blood Gluc values and the development of
systemic metastasis. Once the blood Gluc value reaches over 1
RLU/s, all animals eventually developed detectable systemic
metastasis with both blood Gluc and BLI. The time for reaching
RLU/s of 1 varies among animals from day 14 to 35 after
intracardiac injection of the MDA231BR-G cells. The results are
from four separate experiments.
Found at: doi:10.1371/journal.pone.0008316.s002 (0.35 MB
DOC)
Table S2 Experimental data of orthotopic tumor growth with
caliper and Gluc blood measurements. Size-matched tumor
growth data of both total tumor volume and viable tumor volume
with MDA-MB-231BR tumors-expressing Gluc.(All volumes are
in mm
3, n=11)
Found at: doi:10.1371/journal.pone.0008316.s003 (0.03 MB
DOC)
Suppporting Information S1 Mathematical modeling of total
tumor and the viable tumor volume. A mathematical modeling
approach to correlate the caliper measurement to the total tumor
volume, and to correlate the blood Gluc assay to the viable tumor
burden.
Found at: doi:10.1371/journal.pone.0008316.s004 (0.08 MB
DOC)
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